Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to IgAN
Related studies linked through entity extraction aliases.
FXS6837 for the Treatment of IgAN Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Efficacy and Safety Study of HS-10542 for IgA Nephropathy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Ravulizumab in Pediatric Participants With Primary IgAN
- Status
- RECRUITING
- Phase
- PHASE3
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
- Status
- RECRUITING
- Phase
- PHASE2
Atacicept in Multiple Glomerular Diseases
- Status
- RECRUITING
- Phase
- PHASE2
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
- Status
- RECRUITING
- Phase
- PHASE3
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
- Status
- TERMINATED
- Phase
- PHASE2
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
- Status
- TERMINATED
- Phase
- PHASE2
Safety and Efficacy Study of VIS649 for IgA Nephropathy
- Status
- COMPLETED
- Phase
- PHASE2
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
- Status
- TERMINATED
- Phase
- PHASE2
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
- Status
- TERMINATED
- Phase
- PHASE4